Guardian Pharmacy Services, Inc. GRDN
41.21
(0.58)
(1.39%)
as of 25 Sep
- Market cap
- $2.7B
- P/E
- 39.2×
Follow GRDN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
39.88 | 44.31 | 38.09 | 40.35 |
+8 more quarters Free account |
P/S ratio |
1.81 | 1.64 | 1.30 | 1.17 | |
P/FCF ratio |
33.23 | 33.93 | 23.26 | 23.90 | |
P/Operating CF |
88.31 | 393.38 | 54.25 | 57.85 | |
P/B ratio |
10.29 | 10.26 | 8.61 | 8.34 | |
Price to Tangible BV |
16.44 | 17.64 | 15.68 | 16.80 | |
EV/Sales |
1.78 | 1.62 | 1.28 | 1.17 | |
EV/EBITDA |
23.90 | 23.49 | 19.47 | 20.28 | |
EV/Operating CF |
26.30 | 26.57 | 18.46 | 18.54 | |
EV/FCF |
32.59 | 33.56 | 22.92 | 23.93 | |
Quick Ratio |
1.26 | 1.10 | 1.04 | 0.88 | |
Current Ratio |
1.65 | 1.46 | 1.38 | 1.22 | |
Net Debt/EBITDA |
(3.40) | (2.74) | (1.80) | (1.64) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
3.66 | 3.83 | 3.95 | 3.77 | |
Operating CF/Net income |
1.37 | 0.46 | 1.65 | 2.87 | |
Capex/Depreciation |
(0.84) | (0.79) | (0.74) | (0.89) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.89% | 17.42% | 13.77% | 15.46% | |
Intangible Assets out of Total Assets |
0.22 | 0.23 | 0.24 | 0.25 | |
Share Based Compensation of Revenue |
0.83% | 0.55% | 0.27% | 1.15% | |
Graham Net Nets |
0.03 | 0.02 | 0.01 | 0.00 | |
Graham Number |
9.80 | 8.38 | 7.88 | 6.78 | |
Earnings Yield |
2.51% | 2.26% | 2.63% | 2.48% | |
Free Cash Flow Yield |
3.01% | 2.95% | 4.30% | 4.18% | |
Revenue per Share |
5.55 | 5.32 | 6.37 | 6.08 | |
Operating CF per Share |
0.47 | 0.10 | 0.55 | 0.45 | |
Capex per Share |
(0.08) | (0.07) | (0.07) | (0.08) | |
Free Cash Flow per Share |
0.40 | 0.02 | 0.49 | 0.37 | |
Cash per Share |
1.42 | 1.02 | 1.05 | 0.59 | |
Shareholders Equity per Share |
4.07 | 3.67 | 3.49 | 3.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.07 | 3.67 | 3.49 | 3.15 | |
Free Cash Flow |
25.14 | 1.31 | 30.37 | 22.96 | |
Working Capital |
100.63 | 74.64 | 60.93 | 36.33 | |
Capital Expenditures |
(4.89) | (4.75) | (4.23) | (5.21) | |
Net Current Asset Value |
68.73 | 40.67 | 26.90 | 3.74 | |
EV/EBIT |
30.44 | 30.48 | 25.45 | 27.80 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
6.22% | 3.95% | 5.26% | 2.60% | |
Price to Operating Income |
31.04 | 30.82 | 25.82 | 27.76 | |
| Other line items | |||||
Average Receivables |
98.95 | 104.56 | 99.38 | 98.56 | |
Average Payables |
106.60 | 105.11 | 109.31 | 114.27 | |
Average Inventory |
47.30 | 45.30 | 41.95 | 46.54 | |
Average Assets |
399.96 | 380.47 | 366.73 | 369.03 | |
Average Common Equity |
218.66 | 197.82 | 183.95 | 164.70 |
Columns are period end dates